PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
Hormone Receptor Positive Malignant Neoplasm of Breast
DEVICE: MammaPrint
Difference in recommended adjuvant chemotherapy treatment, The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result. A Chi-square test will be performed for the comparison of the two proportions., 30 days
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result.